Abstract
Background: Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae that can be self-limiting or progressive according to the immunological status of the host organism. Aim and objectives: We present the demographic and clinical characteristics of lepromatous leprosy (LL) patients who had Covid-19 infection. Materials and methods: This study recruited patients hospitalized in Elazığ Leprosy Hospital. Details of the patients were collected as follows: age, gender, presence of comorbidity, leprosy classification, clinical presentation, presence of leprosy reactions and complaints at the time of admission; laboratory and computed tomography (CT) findings and treatments applied. Results: This study included 9 patients with lepromatous leprosy (LL classification). Six patients were PCR positive for SARS-CoV-2, 7 patients had thoracic CT involvement. The mean age was 78.7 years (range 65–95). Complaints on admission included fatigue (n:7), cough (n:4) and fever (n:3) followed by sore throat (n:1), headache (n:1) and dysphonia (n:1). Two patients were asymptomatic, PCR positivity was detected in one and CT positivity was detected in another during screening. All patients received treatment with favipiravir and enoxaparin. No leprosy reactions occurred. All patients were discharged with recovery after completion of treatment. Conclusion: We expected that the risk for catching COVID-19 may be higher in LL patients who have a cellular immunity deficiency, and that the course of the infection may be more severe in COVID-19-infected LL patients, for the same reason. However, we have seen a decrease in the clinical severity of the COVID-19 and no patient losses. We conclude that this situation may be due to the drugs used for leprosy treatment. These immune-modulating drugs may cause a decrease in the clinical severity of the COVID-19, but we need larger studies on this subject.
Highlights
Leprosy is a mycobacterial infection affecting peripheral nerves and the immune system
The prevalence and incidence rates for leprosy have been significantly reduced as a result of the control strategies of the World Health Organization (WHO), new cases still appear in the world
Nine patients were included in the study, all with the lepromatous clinical form of leprosy
Summary
Leprosy is a mycobacterial infection affecting peripheral nerves and the immune system. The prevalence and incidence rates for leprosy have been significantly reduced as a result of the control strategies of the World Health Organization (WHO), new cases still appear in the world. It is a serious, chronic, infectious disease that can vastly change a person’s life.[1] One of the important points in the course of the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is how is this virus affects patients with other infectious diseases.[1] The World Health Organization (WHO) reported that there are >130 million confirmed cases of COVID-19 worldwide, resulting in 2,930,732 deaths (2.1%). This article describes the clinical characteristics and outcomes in patients with COVID-19 and leprosy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
